Literature DB >> 10497971

A novel Fab-based antivenom for the treatment of mass bee attacks.

R G Jones1, R L Corteling, G Bhogal, J Landon.   

Abstract

The frequency of mass bee attacks has dramatically increased in the Americas following the introduction and spread of the aggressive Africanized 'killer' bee (Apis mellifera scutellata). As yet no specific therapy is available, which led us to develop an ovine Fab-based antivenom as a potential new treatment. Sera from sheep immunized against the venom contained high levels of specific antibodies, as demonstrated by ELISA and by small-scale affinity chromatography, against both whole (A. m. mellifera) venom and purified melittin. A nerve muscle preparation was used to show the myotoxic effects of the venom and neutralization by the antivenom. Antivenom neutralizing ability was also demonstrated using assays for venom phospholipase A2 and in vivo activities. Venom from both European and Africanized bees appeared identical when analyzed by acid-urea gel electrophoresis. This antivenom may therefore provide the first specific therapy for the treatment of mass envenomation by either European or Africanized 'killer' bees.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497971     DOI: 10.4269/ajtmh.1999.61.361

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

1.  Electrophysiological and structural aspects in the frontal cortex after the bee (Apis mellifera) venom experimental treatment.

Authors:  Adrian Florea; Constantin Puică; Mihaela Vinţan; Ileana Benga; Constantin Crăciun
Journal:  Cell Mol Neurobiol       Date:  2011-02-26       Impact factor: 5.046

Review 2.  The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.

Authors:  Adi Lahiani; Ephraim Yavin; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2017-03-16       Impact factor: 4.546

3.  The role of Cryptosporidium parvum-derived phospholipase in intestinal epithelial cell invasion.

Authors:  R C G Pollok; V McDonald; P Kelly; M J G Farthing
Journal:  Parasitol Res       Date:  2003-02-26       Impact factor: 2.289

4.  Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant.

Authors:  Cassandra D Kelly; Chris O'Loughlin; Frank B Gelder; Johnny W Peterson; Laurie E Sower; Nick M Cirino
Journal:  J Immune Based Ther Vaccines       Date:  2007-10-22

5.  Active immunity induced by passive IgG post-exposure protection against ricin.

Authors:  Charles Chen Hu; Junfei Yin; Damon Chau; John W Cherwonogrodzky; Wei-Gang Hu
Journal:  Toxins (Basel)       Date:  2014-01-21       Impact factor: 4.546

6.  Acute ischemic stroke and severe multiorgan dysfunction due to multiple bee stings.

Authors:  Murat Guzel; Handan Akar; Ali Kemal Erenler; Ahmet Baydin; Abdulcelil Kayabas
Journal:  Turk J Emerg Med       Date:  2016-09-29

Review 7.  Bee Updated: Current Knowledge on Bee Venom and Bee Envenoming Therapy.

Authors:  Manuela B Pucca; Felipe A Cerni; Isadora S Oliveira; Timothy P Jenkins; Lídia Argemí; Christoffer V Sørensen; Shirin Ahmadi; José E Barbosa; Andreas H Laustsen
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

8.  Molecularly Imprinted Ligand-Free Nanogels for Recognizing Bee Venom-Originated Phospholipase A2 Enzyme.

Authors:  Anamaria Zaharia; Ana-Mihaela Gavrila; Iuliana Caras; Bogdan Trica; Anita-Laura Chiriac; Catalina Ioana Gifu; Iulia Elena Neblea; Elena-Bianca Stoica; Sorin Viorel Dolana; Tanta-Verona Iordache
Journal:  Polymers (Basel)       Date:  2022-10-07       Impact factor: 4.967

9.  Production of the first effective hyperimmune equine serum antivenom against Africanized bees.

Authors:  Keity Souza Santos; Marco Antonio Stephano; José Roberto Marcelino; Virginia Maria Resende Ferreira; Thalita Rocha; Celso Caricati; Hisako Gondo Higashi; Ana Maria Moro; Jorge Elias Kalil; Osmar Malaspina; Fabio Fernandes Morato Castro; Mário Sérgio Palma
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.